US Patent No: 4,814,436

Number of patents in Portfolio can not be more than 2000

Derivative of .alpha., .alpha.-trehalose and a process for preparing the same

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Derivatives of .alpha.,.alpha.-trehalose-6,6'-fatty acid diester having phosphoric ester groups in the molecule which are useful as a carcinostatic agent. One of the derivatives may be prepared by reacting diphenylphosphoryl chloridate with a derivative of 2,3,2',3'-tetra-O-benzyl-.alpha.,.alpha.-trehalose-6,6'-fatty acid diester. Another derivative may be obtained by substituting benzyl groups at 2,3,2',3' positions of trehalose with hydrogen atoms.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
SS PHARMACEUTICAL CO., LTD.TOKYO5

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Katori, Tatsuhiko Tone, JP 21 103
Kohya, Hidehiko Narita, JP 7 41
Matsuda, Hideaki Natori, JP 104 787
Shibata, Akihiro Takatsuki, JP 62 179

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Wintershall AG (1)
* 4,720,456 Trehalose lipid tetraesters 9 1986
 
SS Pharmaceutical Co., Ltd. (2)
* 4,684,719 .alpha.,.alpha.-trehalose fatty acid diester derivative 32 1985
* 4,612,304 Antitumor formulation containing lipopolysaccharide with trehalose derivatives 7 1985
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
SAWAI PHARMACEUTICAL CO., LTD. (1)
* 5,049,664 Trehalose derivatives 4 1989
 
QUADRANT HOLDINGS CAMBRIDGE LIMITED (1)
6,331,310 Solid dose delivery vehicle and methods of making same 62 2000
 
QDOSE LIMITED (2)
6,290,991 Solid dose delivery vehicle and methods of making same 78 1994
6,565,871 Solid dose delivery vehicle and methods of making same 62 2001
 
QUADRANT DRUG DELIVERY LIMITED (9)
6,632,648 Methods of terminal sterilization of fibrinogen 9 1996
6,468,782 Methods of preserving prokaryotic cells and compositions obtained thereby 25 1997
6,586,006 Solid delivery systems for controlled release of molecules incorporated therein and methods of making same 56 2001
6,811,792 Solid dose delivery vehicle and methods of making same 153 2002
6,893,657 Solid dose delivery vehicle and methods of making same 15 2003
7,056,495 Solid dose delivery vehicle and methods of making same 101 2003
7,785,631 Solid dose delivery vehicle and methods of making same 3 2005
7,780,991 Solid dose delivery vehicle and methods of making same 2 2005
7,744,925 Solid dose delivery vehicle and methods of making same 3 2005
 
NOVARTIS AG (10)
7,871,598 Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use 0 2000
8,168,223 Engineered particles and methods of use 3 2001
7,306,787 Engineered particles and methods of use 25 2002
7,521,069 Methods and compositions for pulmonary delivery of insulin 15 2003
8,404,217 Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use 0 2005
8,715,623 Pulmonary delivery of aminoglycoside 0 2007
8,709,484 Phospholipid-based powders for drug delivery 0 2008
8,246,934 Respiratory dispersion for metered dose inhalers comprising perforated microstructures 3 2010
8,349,294 Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use 0 2010
8,877,162 Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery 0 2012
 
KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (1)
* 5,576,303 Energy-supplementing saccharide source and its uses 7 1994
 
NOVARTIS PHARMA AG (2)
7,300,919 Pulmonary delivery of active fragments of parathyroid hormone 8 2002
7,628,978 Stabilized preparations for use in metered dose inhalers 8 2003
* Cited By Examiner